Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 2/20 | 0.60 |
| ▸ | FEN1 | P39748 | 16/20 | 0.40 |
| ▸ | ALOX5AP | P20292 | 16/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22652321 | 0.88 | GRM5 (0.58) | GRM5FEN1ALOX5APALDH1A1GAA | |
| SCHEMBL19737641 | 0.83 | GRM5 (0.56) | GRM5FEN1ALOX5AP | |
| SCHEMBL91447 | 0.78 | GRM5 (0.54) | GRM5FEN1ALOX5APALDH1A1GAA | |
| SCHEMBL30657929 | 0.78 | GRM5 (0.54) | GRM5FEN1ALOX5APALDH1A1GAA | |
| SCHEMBL15889739 | 0.77 | GRM5 (0.63) | GRM5FEN1ALOX5AP | |
| SCHEMBL16256878 | 0.77 | NNMT (0.53) | GRM5FEN1ALOX5APALDH1A1GAA | |
| SCHEMBL19286094 | 0.76 | GRM5 (0.46) | GRM5FEN1ALOX5APALDH1A1GAA | |
| SCHEMBL21089746 | 0.75 | GRM5 (0.42) | GRM5FEN1ALOX5APALDH1A1GAA | |
| SCHEMBL22225994 | 0.75 | GRM5 (0.45) | GRM5ALDH1A1MAPTHSD17B10 | |
| SCHEMBL18307148 | 0.75 | GRM5 (0.54) | GRM5FEN1ALOX5APALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3856736-A1 | NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS | GenKyoTex Suisse SA (CH) | 2021-08-04 | — | — | EP | disclosed |
| US-10640503-B2 | Imidazopyridines and imidazopyrazines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2020-05-05 | — | — | US | disclosed |
| WO-2020065048-A1 | NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS | GENKYOTEX SUISSE SA (CH) | 2020-04-02 | — | — | WO | disclosed |
| US-20190040058-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRAZINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2019-02-07 | — | — | US | disclosed |
| US-9695168-B2 | Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2017-07-04 | — | — | US | disclosed |
| US-9624229-B2 | Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases | RIGEL PHARMACEUTICALS, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-20140213585-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | RIGEL PHARMACEUTICALS, INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-20130018041-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | RIGEL PHARMACEUTICAL, INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-8309566-B2 | Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases | RIGEL PHARMACEUTICALS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20120245162-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-27 | — | — | US | disclosed |
| US-20120220561-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-30 | — | — | US | disclosed |
| US-20110003798-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2011-01-06 | — | — | US | disclosed |
| US-20090258864-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | RIGEL PHARMACEUTICALS, INC. (US) | 2009-10-15 | — | — | US | disclosed |
| US-7312209-B2 | Acridone inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190040058-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRAZINES AS LSD1 INHIBITORS | KDM5A, KDM1A, KDM1B | GRM5 768/4885FEN1 3278/4885ALOX5AP 2245/4885 |
| US-20140213585-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | JAK2, JAK1, JAK3 | GRM5 1877/4885FEN1 3297/4885ALOX5AP 3801/4885 |
| US-20120245162-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | LTB4R, LTC4S, LTB4R2 | GRM5 1323/4885FEN1 3181/4885ALOX5AP 17/4885 |
| US-20110003798-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | FYN, SYK, RET | GRM5 687/4885FEN1 2666/4885ALOX5AP 3823/4885 |
| US-20120220561-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | LTB4R, LTC4S, LTB4R2 | GRM5 1129/4885FEN1 3090/4885ALOX5AP 17/4885 |
| US-20130018041-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | JAK2, JAK1, JAK3 | GRM5 1888/4885FEN1 3152/4885ALOX5AP 3403/4885 |
| US-20090258864-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | JAK2, JAK1, JAK3 | GRM5 1919/4885FEN1 3081/4885ALOX5AP 3395/4885 |
| US-10640503-B2 | Imidazopyridines and imidazopyrazines as LSD1 inhibitors | KDM5A, KDM1A, KDM1B | GRM5 768/4885FEN1 3278/4885ALOX5AP 2245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.